[{"id":"e06d125e-be2f-4bab-b3eb-1d429ac20566","acronym":"PIPA","url":"https://clinicaltrials.gov/study/NCT02389842","created_at":"2021-01-18T11:23:37.294Z","updated_at":"2024-07-02T16:36:53.435Z","phase":"Phase 1","brief_title":"PIPA: Combination of PI3 Kinase Inhibitors and PAlbociclib","source_id_and_acronym":"NCT02389842 - PIPA","lead_sponsor":"Royal Marsden NHS Foundation Trust","biomarkers":" HER-2 • KRAS • PIK3CA","pipe":" | ","alterations":" KRAS mutation • PIK3CA mutation","tags":["HER-2 • KRAS • PIK3CA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • fulvestrant • pictilisib (GDC-0941) • taselisib (GDC-0032)"],"overall_status":"Unknown status","enrollment":" Enrollment 93","initiation":"Initiation: 03/25/2015","start_date":" 03/25/2015","primary_txt":" Primary completion: 10/31/2018","primary_completion_date":" 10/31/2018","study_txt":" Completion: 01/01/2020","study_completion_date":" 01/01/2020","last_update_posted":"2019-11-19"},{"id":"86016884-d6ee-490d-bf5d-5bac693c02a5","acronym":"","url":"https://clinicaltrials.gov/study/NCT01493843","created_at":"2021-01-18T06:15:28.162Z","updated_at":"2024-07-02T16:37:23.101Z","phase":"Phase 2","brief_title":"Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab With and Without Pictilisib in Previously Untreated Advanced or Recurrent Non-small Cell Lung Cancer","source_id_and_acronym":"NCT01493843","lead_sponsor":"Genentech, Inc.","biomarkers":" PIK3CA • PTEN","pipe":" | ","alterations":" PIK3CA amplification • PTEN-L","tags":["PIK3CA • PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA amplification • PTEN-L"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • carboplatin • paclitaxel • pictilisib (GDC-0941)"],"overall_status":"Completed","enrollment":" Enrollment 501","initiation":"Initiation: 01/20/2012","start_date":" 01/20/2012","primary_txt":" Primary completion: 03/30/2016","primary_completion_date":" 03/30/2016","study_txt":" Completion: 03/30/2016","study_completion_date":" 03/30/2016","last_update_posted":"2017-04-25"},{"id":"6a8a4678-4b73-4636-8220-4f159e37109b","acronym":"","url":"https://clinicaltrials.gov/study/NCT01740336","created_at":"2021-01-18T07:37:00.855Z","updated_at":"2024-07-02T16:37:23.153Z","phase":"Phase 2","brief_title":"A Study of Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo in Participants With Locally Recurrent or Metastatic Breast Cancer","source_id_and_acronym":"NCT01740336","lead_sponsor":"Genentech, Inc.","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • pictilisib (GDC-0941)"],"overall_status":"Completed","enrollment":" Enrollment 183","initiation":"Initiation: 02/06/2013","start_date":" 02/06/2013","primary_txt":" Primary completion: 10/20/2015","primary_completion_date":" 10/20/2015","study_txt":" Completion: 12/10/2015","study_completion_date":" 12/10/2015","last_update_posted":"2017-04-24"},{"id":"20909a87-71be-4262-a5cb-19127e76935c","acronym":"","url":"https://clinicaltrials.gov/study/NCT00928330","created_at":"2021-01-18T03:35:43.625Z","updated_at":"2024-07-02T16:37:27.951Z","phase":"Phase 1","brief_title":"Trastuzumab and Trastuzumab-MCC-DM1 Administered Intravenously and GDC-0941 Administered Orally to Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed on Previous Trastuzumab-Based Therapy","source_id_and_acronym":"NCT00928330","lead_sponsor":"Genentech, Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kadcyla (ado-trastuzumab emtansine) • pictilisib (GDC-0941)"],"overall_status":"Completed","enrollment":" Enrollment 57","initiation":"Initiation: 07/01/2009","start_date":" 07/01/2009","primary_txt":" Primary completion: 01/01/2014","primary_completion_date":" 01/01/2014","study_txt":" Completion: 01/01/2014","study_completion_date":" 01/01/2014","last_update_posted":"2016-11-02"},{"id":"5538e537-d6e2-4b8f-95f1-84b82759df58","acronym":"","url":"https://clinicaltrials.gov/study/NCT01437566","created_at":"2021-01-18T05:57:00.009Z","updated_at":"2024-07-02T16:37:28.007Z","phase":"Phase 2","brief_title":"Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Participants Resistant to Aromatase Inhibitor Therapy","source_id_and_acronym":"NCT01437566","lead_sponsor":"Genentech, Inc.","biomarkers":" HER-2 • ER • PIK3CA","pipe":" | ","alterations":" ER positive • HER-2 negative • PIK3CA mutation","tags":["HER-2 • ER • PIK3CA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • pictilisib (GDC-0941) • apitolisib (GDC-0980)"],"overall_status":"Completed","enrollment":" Enrollment 318","initiation":"Initiation: 10/01/2011","start_date":" 10/01/2011","primary_txt":" Primary completion: 04/01/2016","primary_completion_date":" 04/01/2016","study_txt":" Completion: 04/01/2016","study_completion_date":" 04/01/2016","last_update_posted":"2016-11-02"}]